Thema: US92337R1014
VERA, US92337R1014
new-york-stock-exchange-1708834_1920.jpg - Foto: THN
Vera Therapeutics stock: ORIGIN 3 backs 2026 FDA filing plan
Vera Therapeutics stock is in focus after positive ORIGIN 3 data for TRUTAKNA. The company plans a supplemental FDA filing before year-end.
ad-hoc-news.de, heute 01:17 Uhr
VERA, US92337R1014
Vera Therapeutics stock: Leerink keeps a USD 34.00 target ...
Leerink kept a Hold rating and USD 34.00 target on October 27, 2026. For Vera Therapeutics stock, second-quarter GAAP loss was USD 109.5 million.
ad-hoc-news.de, 28.10.26 06:50 Uhr
VERA, US92337R1014
Vera Therapeutics stock: ORIGIN 3 results support Vera Therapeutics ...
ORIGIN 3 cut serious events to 7 percent versus 15 percent for placebo. The next date for Vera Therapeutics stock is November 5, 2026.
ad-hoc-news.de, 24.10.26 01:38 Uhr
VERA, US92337R1014
Vera Therapeutics schedules ORIGIN 3 webcast: USD 34 target ...
Leerink set a USD 34 target for Vera Therapeutics stock on October 12, 2026. ORIGIN 3 data webcast is set for October 22.
ad-hoc-news.de, 21.10.26 02:28 Uhr
Analyst, Confidence
Analyst Confidence Fuels Optimism for Vera Therapeutics
Vera Therapeutics US92337R1014
boerse-global.de, 17.01.26 09:12 Uhr
Vera, Therapeutics
Vera Therapeutics Receives Priority Review for Atacicept ...
